Clinical isolate of a Xanthomonas maltophilia strain producing L-1-deficient and L-2-inducible beta-lactamases

Chemotherapy. 1995 Mar-Apr;41(2):121-4. doi: 10.1159/000239332.

Abstract

Xanthomonas maltophilia produces two inducible beta-lactamases, L-1 and L-2, and resists the antimicrobial activity of beta-lactam antibiotics including carbapenems. L-1 has carbapenemase activity and L-2 is a cephalosporinase. It has been suggested that these beta-lactamases share regulatory components. We isolated a recent clinical X. maltophilia strain susceptible to carbapenems and resistant to almost all the other beta-lactam antibiotics tested. beta-Lactamase induction with cefotaxime showed that the clinical isolate had low-level expression of L-1 beta-lactamase but remained inducible for L-2 enzyme. The possible relationship of this enzyme to carbapenem sensitivity is considered.

Publication types

  • Comparative Study

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Cephalosporinase / biosynthesis*
  • Enzyme Induction
  • Humans
  • Microbial Sensitivity Tests
  • Penicillinase / biosynthesis*
  • Penicillinase / deficiency
  • Species Specificity
  • Xanthomonas / classification
  • Xanthomonas / enzymology*
  • Xanthomonas / isolation & purification
  • beta-Lactams

Substances

  • Anti-Bacterial Agents
  • beta-Lactams
  • Cephalosporinase
  • Penicillinase